Lahjavida (La-ya-vee-da) translates to “the gift of life,” a reminder of why we innovate: to help people live not only longer, but better. Our work centers on developing next-generation cancer therapies that are designed to be both potentially more efficacious and profoundly more tolerable for patients.
Lahjavida Bio is pioneering a novel class of small-molecule precision therapeutics built on a simple but transformative idea:
Originating from a breakthrough discovery in tumor-targeting dye chemistry made in 2009 by our founder, chemist and inventor Lyle Small, this concept has grown into a scalable drug-delivery platform designed to fundamentally improve how cancer medicines behave inside the body.
We are advancing a pipeline of proprietary Dye-Drug Conjugates (DDCs) that selectively accumulate in cancer cells while limiting exposure to healthy tissues. Our goal is straightforward: to make cancer therapy more precise, more effective, and significantly less toxic.
Lower systemic toxicity in preclinical models
Demonstrated through in vivo imaging and biodistribution studies
Avoiding the manufacturing, cost, and complexity challenges of biologic ADCs
Lahjavida Bio is led by seasoned scientists and biotech executives with deep expertise in oncology drug development, pharmaceutical operations, and advanced dye chemistry. Our team brings decades of global experience across R&D, CMC, translational medicine, and commercialization—advancing novel therapeutics from concept to clinic.
We’ve developed breakthrough technologies, raised capital, led IPO and M&A transactions, and helped deliver therapies to patients worldwide. This combination positions Lahjavida Bio to build next-generation, tumor-selective therapies that broaden what small-molecule precision oncology can achieve.